Mecapegfilgrastim is a Recombinant Protein owned by Jiangsu Hengrui Medicine, and is involved in 11 clinical trials, of which 4 were completed, 3 are ongoing, and 4 are planned.

Pegfilgrastim (Pegylated rhG-CSF) specifically stimulates and regulates the proliferation, differentiation of granulocyte series progenitor cell which then promotes maturity and release of neutrophils. Chemotherapy causes secondary effects on variety of normal cells including hematopoietic elements of the bone marrow and causes neutropenia. The drug candidate releases the neutrophils through influencing hematopoietic stem and progenitor cell, micro-environment of bone marrow and apoptosis. Thus, the drug candidate alleviates the condition.

The revenue for Mecapegfilgrastim is expected to reach a total of $7.8bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Mecapegfilgrastim NPV Report.

Mecapegfilgrastim is currently owned by Jiangsu Hengrui Medicine.

Mecapegfilgrastim Overview

Mecapegfilgrastim (Aido, Thiopefilgrastim) is a recombinant human granulocyte stimulating factor. It is formulated as pegylated solution for subcutaneous route of administration. Mecapegfilgrastim is indicated for the treatment of adult patients with neutropenia and infection caused by radiotherapy and chemotherapy for non-myeloid malignant tumors.

Jiangsu Hengrui Medicine Overview

Jiangsu Hengrui Medicine (Jiangsu Hengrui) is a biopharmaceutical company that focuses on the research, development, manufacture, and distribution of novel pharmaceutical products. Its product portfolio includes anti-tumor drugs, surgical drugs, contrast agents, angiomyocardiac drugs, and antibiotics. The company is also developing pipeline products for the treatment of cancer, Crohn’s disease, anemia, diabetes, atopic dermatitis, chronic bone disease, blood pressure, and hypercholesterolemia. Jiangsu Hengrui has R&D facilities in China, the US and Japan. The company offers products through its sales and distribution network in China, the US, Japan, Germany Switzerland, and Australia. Jiangsu Hengrui is headquartered in Lianyungang, Jiangsu Province, China.

The company reported revenues of (Renminbi) CNY25,905.5 million for the fiscal year ended December 2021 (FY2021), a decrease of 6.6% over FY2020. In FY2021, the company’s operating margin was 18%, compared to an operating margin of 25.3% in FY2020. In FY2021, the company recorded a net margin of 17.5%, compared to a net margin of 22.8% in FY2020. The company reported revenues of CNY5,717.3 million for the third quarter ended September 2022, an increase of 20.4% over the previous quarter.

Quick View – Mecapegfilgrastim

Report Segments
  • Innovator (NME)
Drug Name
  • Mecapegfilgrastim
Administration Pathway
  • Subcutaneous
Therapeutic Areas
  • Toxicology
Key Companies
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.